Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Large-Scale Exercise of the 12th Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions)

For the 12th Stock Acquisition Rights allocated to EVO FUND and subject to an exercise price adjustment clause, rights equivalent to 3,026,000 shares were exercised from 2 September to 9 September 2026. As a result, the number of unexercised rights decreased from 80,960 to 50,700.

Worth reading
72In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
3026000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Status of large-scale exercise of the 12th Stock Acquisition Rights issued through a third-party allotment, with an exercise price adjustment clause

発行・処分する株式数

Number of shares delivered since the previous disclosure: 3,026,000 shares (all newly issued shares; transferred treasury shares: 0 shares)

Intended allottee
EVO FUND (allottee of the stock acquisition rights)
発行済株式総数

The number of Stock Acquisition Rights exercised since the previous disclosure represented 30.26% of the total 100,000 rights issued. The ratio of the 3,026,000 shares delivered in this exercise to the 16,209,000 issued shares as of the previous disclosure is not stated.

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Subject to an exercise price adjustment clause. The exercise prices during the period were ¥126, ¥104 and ¥111. The adjustment floor is Not disclosed.
Number of Stock Acquisition Rights
Total issued: 100,000 rights. Unexercised rights were 80,960 as of the previous disclosure and 50,700 as of the current date. Rights exercised in this period: 30,260.
Procedures under the Corporate Code of Conduct
In accordance with Article 436, paragraph 5, item 4 of the Enforcement Rules for the Listing Regulations of the Tokyo Stock Exchange, the purchase agreement provides that the prohibition on excessive exercise does not apply when the exercise price is at least the closing price on 22 July 2026, the date of the resolution approving the issuance.
Most recent equity financing
Timing Announced 22 July 2026; issued 7 August 2026 / Type 12th Stock Acquisition Rights issued through a third-party allotment, with an exercise price adjustment clause, and 3rd unsecured corporate bonds (private placement bonds) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalStatus of large-scale exercise of the 12th Stock Acquisition Rights issued through a third-party allotment, with an exercise price adjustment clause
Number of shares to be issued or disposed ofNumber of shares delivered since the previous disclosure: 3,026,000 shares (all newly issued shares; transferred treasury shares: 0 shares)
Intended allotteeEVO FUND (allottee of the stock acquisition rights)
Dilution RateThe number of Stock Acquisition Rights exercised since the previous disclosure represented 30.26% of the total 100,000 rights issued. The ratio of the 3,026,000 shares delivered in this exercise to the 16,209,000 issued shares as of the previous disclosure is not stated.
Total number of issued sharesAs of the previous disclosure: 16,209,000 shares (including 198 treasury shares) → Not disclosed
Exercise priceSubject to an exercise price adjustment clause. The exercise prices during the period were ¥126, ¥104 and ¥111. The adjustment floor is Not disclosed.
Number of Stock Acquisition RightsTotal issued: 100,000 rights. Unexercised rights were 80,960 as of the previous disclosure and 50,700 as of the current date. Rights exercised in this period: 30,260.
Procedures under the Corporate Code of ConductIn accordance with Article 436, paragraph 5, item 4 of the Enforcement Rules for the Listing Regulations of the Tokyo Stock Exchange, the purchase agreement provides that the prohibition on excessive exercise does not apply when the exercise price is at least the closing price on 22 July 2026, the date of the resolution approving the issuance.
Most recent equity financingTiming Announced 22 July 2026; issued 7 August 2026 / Type 12th Stock Acquisition Rights issued through a third-party allotment, with an exercise price adjustment clause, and 3rd unsecured corporate bonds (private placement bonds) / Amount Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Under the rules of the Tokyo Stock Exchange, the prohibition on excessive exercise does not apply when the exercise price is at least the closing price on 22 July 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Large-Scale Exercise of the 12th Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori